I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $371.25M

Company

Location

Date

Amt. (M)

Details


Acadia Pharmaceuticals Inc.

San Diego, Calif.

3/28

$25

Acadia raised $25M in a private financing led by Oxford Bioscience Partners; other investors were OrbiMed Advisors LLC, Federated Kaufmann Fund, LD Pensions, Hambrecht & Quist Capital Management LLC, ABN AMRO Ventures, Carnegie Fund II Biotechbridge and Dansk Kapitalanlaeg Aktieselskab

Agensys Inc.

Santa Monica, Calif.

3/5

--

Agensys secured a $3M line of credit from Silicon Valley Bank

Cellzome AG

Munich, Germany

3/25

€30
(US$32.23)

Cellzome raised US$32.23M in its third round led by Invesco Private Capital, Biofrontier Partners, SG Asset Management and Yamanouchi Venture Capital; other investors were Atlas Ventures, Advent International, Index Ventures, Heidelberg Innovation, Schroder Ventures Life Sciences, Sofinnova Partners and Stelios Papadopoulos

Chiasma

Netanya, Israel

3/25

$2

Chiasma received $2M in seed financing from InnoMed

Corus Pharma
Inc.

Seattle, Wash.

3/7

$40

Corus raised $40M in a Series B preferred stock offering led by JPMorgan Partners, RBC Capital Partners and Novo Nordisk A/S; other investors were Burrill & Co., OrbiMed Advisors,Cascade Investment, Washington Research Foundation, Anthem Venture Partners, MDS Capital and Integra Ventures

FRIZ Biochem GmbH

Munich, Germany

3/28

€3
(US$3.26)

FRIZ raised US$3.26M in the first tranche of a Series B financing led by Global Life Science Ventures; other investors were DRF Beteiligungsgesellschaft

GenVault Corp.

Carlsbad, Calif.

3/24

$10

GenVault raised $10M in a Series A round from funds managed by Domain Associates LLC

Hypnion Inc.

Worcester, Mass.

3/17

$47.5

Hypnion raised $47.5M in a Series B round co-led by Forward Ventures and MPM Capital; other investors were Advanced Technology Ventures, S.R. One Ltd., Jafco Co. Ltd., Coastview Capital, Oxford Bioscience Partners, Flagship Ventures and GIMV Venture Capital

Iomai Corp.

Gaithersburg, Md.

3/31

$2

Iomai raised an additional $2M in its Series C, bringing the total for the round to $56M; the $2M was provided by AIG Global Investment Corp.

OncoGenome
Sciences SA

Liege, Belgium

3/12

€14
(US$15.43)

OncoGenome raised US$15.43M in a financing co-led by funds advised by PolyTechnos Venture-Partners and Life Sciences Partners; other investors were Technowal SA, Meusinvest and S.I.B.L.

Peptimmune Inc.

Cambridge, Mass.

3/11

$41.2

Peptimmune raised $41.2M in its first round, co-led by New Enterprise Associates and MPM Capital; other investors were Prism Venture Partners, Vanguard Ventures, Hunt Ventures LP and Boston Medical Investors Inc.

Sopherion
Therapeutics Inc.

New Haven, Conn.

3/7

$26

Sopherion raised $26M in its first round led by TL Ventures; other investors were HealthCap KB, ProQuest Investments, Johnson & Johnson Development Corp., Intersouth Partners, Seaflower Ventures, Connecticut Innovations Inc. and GE Life Science and Technology Finance

StemCo
Biomedical Inc.

Research Triangle Park, N.C.

3/18

$9.8

StemCo raised $9.8M in a Series B round led by Intersouth Partners and The Aurora Funds; other investors were Becton Dickinson Ventures, The Trelys Funds LP, Tall Oaks Capital Partners and unnamed individuals

Synta Pharmaceuticals Inc.

Lexington, Mass.

3/28

$75.3

Synta raised $75.3M in a Series B round; investors were Keith Gollust, Bruce Kovner, Robert Day, Stanley Druckenmiller, the Wolfensohn Family Foundation and various other undisclosed management consulting and financial institution partners

Targacept Inc.

Winston-Salem, N.C.

3/19

$14

Targacept raised another $14M in its second round, bringing the total raised to $60M; investors were Oxford Bioscience Partners, Jafco Co. Ltd., Cogene Biotech Ventures, Bison Capital and Rock Castle Ventures

UroGene SA

Genopole, France

3/19**

€12
(US$12.68)

UroGene raised US$12.68M in a round led by SGAM; other investors that participated were GenAvent and Capricorn Venture Partners

Zealand
Pharma A/S

Glostrup, Denmark

3/27
(US$5.45)

€5
BankInvest

Zealand raised US$5.45M in a financing led by

Zelos
Therapeutics Inc.

Waltham, Mass.

3/24
(US$9.4)

C$14

Zelos raised US$9.4M in a first round led by Seaflower Ventures and VenGrowth Capital Partners Inc.; Genesys Capital Partners also participated

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $74M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering Event

Details (Date)


Access Pharmaceuticals
Inc.
(AMEX:AKC)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

ND

Milestone
payment

Access received a payment following marketing approval in France for Zindaclin (3/13)

Aderis Pharmaceuticals*

Fujisawa Healthcare Inc.

$2

Milestone payment

Aderis received a $2M payment in connection with the final report from a Phase II study of DTI-0009, which is being developed to control heart rate during atrial fibrillation (3/19)

ArQule Inc.
(ARQL)

Pfizer Inc.

$5

Equity investment

ArQule received the $5M investment for achieving its 2002 collaboration goals (3/18)

Avigen Inc.
(AVGN)

Bayer AG
(Germany)

$2.5

Milestone
payment

Avigen received the payment as part of an option agreement to support the hepatic route of administration for Coagulin-B (3/3)

Enanta
Pharmaceuticals
Inc.*

Chiron Corp.

ND

Milestone
payment

Enanta received the payment after completing the first phase of research for the discovery and development of small-molecule therapeutics for the hepatitis C virus (3/12)

Gamida-Cell
Ltd.*
(Israel)

Teva
Pharmaceutica
Industries Ltd.
(Israel)

$3

Investment

Teva invested $3M in Gamida-Cell, which developed a technology designed to expand the population of stem cells with minimal differentiation (3/12)

ImClone
Systems Inc.
(IMCL)

Bristol-Myers
Squibb Co.

$60

Milestone
payment

ImClone received the $60M payment for reaching the one-year anniversary of the signing of the companies' amended agreement for Erbitux (3/6)

Kosan Biosciences Inc. (KOSN)

Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson)

ND

Milestone payment

Kosan received a payment after J&J identified a Kosan-generated macrolide antibiotic that meets the preclinical criteria of a new chemical entity specified under their collaboration (3/26)

Ligand Pharmaceuticals Inc. (LGND)

Eli Lilly and Co.

$1.5

Milestone payment

Ligand received a $1.5M milestone payment from Lilly, which advanced into Phase II trials LY818 for Type II diabetes and metabolic diseases (3/21)

Metabolex Inc.*

Yamanouchi Pharmaceutical Co. Ltd. (Japan)

ND

Milestone payment

Metabolex received the milestone payment when Yamanouchi selected three targets for screening as part of their collaboration (3/18)

Syn X Pharma Inc.* (Canada)

Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson)

ND

Milestone payment

Syn X received the payment as part of its agreement with Ortho-Clinical for Alzheimer's disease technology for human in vitro diagnostic applications (3/4)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed; AMEX = American Stock Exchange